These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8874867)

  • 1. Interaction of reteplase with heparin. A comparison between reteplase and alteplase.
    Rijken DC; Jie AF
    Blood Coagul Fibrinolysis; 1996 Jul; 7(5):561-6. PubMed ID: 8874867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.
    Gurbel PA; Serebruany VL; Shustov AR; Bahr RD; Carpo C; Ohman EM; Topol EJ
    J Am Coll Cardiol; 1998 Jun; 31(7):1466-73. PubMed ID: 9626821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.
    Noble S; McTavish D
    Drugs; 1996 Oct; 52(4):589-605. PubMed ID: 8891469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reteplase: a new thrombolytic for the treatment of acute myocardial infarction.
    Wooster MB; Luzier AB
    Ann Pharmacother; 1999 Mar; 33(3):318-24. PubMed ID: 10200858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of plasminogen activators and plasminogen with heparin: effect of ionic strength.
    Rijken DC; de Munk GA; Jie AF
    Thromb Haemost; 1993 Nov; 70(5):867-72. PubMed ID: 8128448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reteplase but not alteplase affects early soluble PECAM-1 and P-selectin release in patients with acute myocardial infarction.
    Gurbel PA; Dalesandro MR; Serebruany VL
    Thromb Haemost; 1998 Oct; 80(4):725. PubMed ID: 9799011
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
    Grunwald MR; Hofmann LV
    J Vasc Interv Radiol; 2004 Apr; 15(4):347-52. PubMed ID: 15064337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of reteplase with alteplase for acute myocardial infarction.
    Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators
    N Engl J Med; 1997 Oct; 337(16):1118-23. PubMed ID: 9340503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism.
    Tebbe U; Graf A; Kamke W; Zahn R; Forycki F; Kratzsch G; Berg G
    Am Heart J; 1999 Jul; 138(1 Pt 1):39-44. PubMed ID: 10385761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model.
    Martin U; Fischer S; Kohnert U; Rudolph R; Sponer G; Stern A; Strein K
    J Cardiovasc Pharmacol; 1991 Jul; 18(1):111-9. PubMed ID: 1719279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries.
    Hasdai D; Holmes DR; Topol EJ; Berger PB; Criger DA; Hochman JS; Bates ER; Vahanian A; Armstrong PW; Wilcox R; Ohman EM; Califf RM
    Eur Heart J; 1999 Jan; 20(2):128-35. PubMed ID: 10099909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
    Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
    Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fresh look at the molecular pharmacology of plasminogen activators: from theory to test tube to clinical outcomes.
    Smalling RW
    Am J Health Syst Pharm; 1997 Nov; 54 Suppl 1():S17-22. PubMed ID: 9397233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.
    Moser M; Nordt T; Peter K; Ruef J; Kohler B; Schmittner M; Smalling R; Kübler W; Bode C
    Circulation; 1999 Nov; 100(18):1858-64. PubMed ID: 10545429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
    Lancet; 1995 Aug; 346(8971):329-36. PubMed ID: 7623530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction.
    Hoffmeister HM; Kastner C; Szabo S; Beyer ME; Helber U; Kazmaier S; Baumbach A; Wendel HP; Heller W
    Am J Cardiol; 2000 Aug; 86(3):263-8. PubMed ID: 10922430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of the RAPID 1 and RAPID 2 thrombolytic trials in acute myocardial infarction.
    Weaver WD
    Eur Heart J; 1996 Sep; 17 Suppl E():14-20. PubMed ID: 11823998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on reteplase in thrombotic occlusive disorders.
    Simpson D; Siddiqui MA; Scott LJ; Hilleman DE
    BioDrugs; 2007; 21(1):65-8. PubMed ID: 17263591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.